Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Do you routinely offer post-operative radiotherapy for resected retroperitoneal sarcomas?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Allegheny Health Network, Pittsburgh

I do not routinely offer post-operative RT for resected RP sarcomas. Our approach is to offer pre-op. If pre-op is not given, regardless of R0/1 resection, we do not offer post-op. In these case, we will follow with surveillance scans and if recurrence is noted consider pre-op followed by surgical r...

How do you manage pneumonitis in patients with Stage III NSCLC receiving durvalumab?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Cedars-Sinai Medical Center

Pneumonitis is a concern following chemoradiation (CRT) alone, and the addition of durvalumab leads to increased caution. Patients on the durvalumab arm in the PACIFIC trial, had some increase in pulmonary adverse events. Any-grade cough (35.4%) and pneumonitis or radiation pneumonitis (33.9%) were ...

Does consolidation durvalumab increase the risk of pneumonitis in Stage III NSCLC?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Wexner Medical Center at The Ohio State University

Given the heterogeneity of pneumonitis presentation, the presence of pre-checkpoint inhibitor chest/mediastinal irradiation (by definition in this trial), and the other risk factors often seen in this population (COPD/emphysema, current/past smoking history), it is a real challenge to decipher pulmo...

What is the best treatment regimen for a fungating SCCa of the scrotum arising from untreated genital warts invading the groin and base of the penis with bilateral inguinal nodes?

4
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center

This is a case where I would like to see the patient and the imaging before giving you my opinion. Management in this situation will take a multidisciplinary approach with med onc, urology, and possibly a colorectal surgeon being involved in addition to rad onc. I don’t think there is a single best ...

What RT dose do you recommend for carcinoma in situ of the glottic larynx?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Iowa

I use 2.25 Gy/fx per the Yamazaki randomized trial (PMID: 16169681), 56.25 Gy to 63 Gy depending on lesion bulk. Sometimes the laryngeal biopsy may not have been deep enough to detect invasion or only a portion of a larger lesion was biopsied, leaving the possibility of invasion remaining. We discus...

When do you consider total neoadjuvant therapy (chemotherapy and chemoradiation) for rectal cancer?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Wisconsin

My practice, and that of my group, has moved more towards a TNT model for stage II and III patients, though I think we are all looking for the PROSPECT data to be finalized. NCCN has adopted TNT as a possible consideration, and other groups are considering this more and more (Cercek et al, Jama Onco...

How does the presence of lymphangitic spread in a single lobe impact your management strategy for locally advanced NSCLC?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Toronto

in my anecdote of n=1 I included the entire lobe as CTV/ITV - chemoRT 60/30 followed by durva. Provided lung constraints are met I would suggest to include entire lobe as is at risk

Would you electively treat the neck for a completely resected parotid carcinoma ex pleomorphic adenoma with negative lymph node sampling?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Jacob E Locke MD PA

For positive margin disease with aggressive SCC tumor (PNI, LVSI) involving up to the stylomastoid foramen, and neck nodes negative (except for an involved 'neurovascular bundle' at lvl 3), what doses would you use?

How would you approach a patient with Gleason 9 prostate cancer and regional lymphadenopathy as well as inguinal lymphadenopathy (M1a) but no bone metastases?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · UC San Diego

Definitely warrants a balanced discussion. Systemic therapy as the mainstay is definitely the right answer--long-term ADT for sure, at minimum. I think offering to treat the prostate with RT is fair, based on STAMPEDE. For a fit patient with good life expectancy, I would explain to the patient that ...

Do you routinely use bolus for treatment of early stage glottic cancer?

3
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Banner MD Anderson Cancer Center

Our group routinely uses IMRT to treat early glottic cancers, with the object of reducing carotid and skin toxicity. As such, we treat the entire larynx with a 5 mm PTV expansion and see good coverage of the anterior commissure in general. We do not add bolus routinely. This might not apply to a ver...